ENPP3

ENPP3

ENPP3 Overview

Molecule Name
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3
Synonyms
ENPP3,CD203c,NPP3,E-NPP3,PD-Ibeta,NPPase,PDNP3
Drug Development Progress
Drugs in Clinical Trials4
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
EC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Background
The human NPP family contains seven members which can be classified into two groups according to their substrate preferences. The first class comprises the nucleotide-degrading proteins NPP1, 3 and 4. NPP3 (CD203c, ENPP3) is expressed in multiple organs, including on epithelial and mucosal surfaces, and notably on basophils and mast cells. Activation of basophils by antigen-bound IgE leads to release of inflammatory mediators and rapid upregulation of NPP3 to the cell surface. This protein is in fact a common marker for diagnosing allergen sensitivity with patient basophils by flow cytometry. Basophils and mast cells mediate the response to certain pathogens, as well as acute and chronic allergic reactions. Following activation, these cells release ATP, which further stimulates them in an autocrine manner. NPP3 upregulation serves to degrade ATP and suppress chronic allergic inflammation (but not the acute response).

ENPP3 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
XmAb-819XmAb-819Phase 1 ClinicalXencor Inc
Carcinoma, Renal Cell; Kidney Neoplasms
Details
JNJ-89862175JNJ-89862175Phase 1 ClinicalJanssen Research & Development Llc
Solid tumours
Details
ALY-301ALY-301; GTX-B001Phase 1 ClinicalAlys Pharmaceuticals Inc
Chronic Urticaria; Symptomatic Dermographism; Urticaria
Details
JNJ-87890387JNJ-87890387Phase 1 ClinicalJanssen Research & Development Llc
Neoplasms; Solid tumours
Details